Psoriasis is a chronic skin disorder with an autoimmune component primarily driven by overactive T cells culminating in an excessive inflammatory response. Patients have reported clearance of their psoriasis after organ transplant, due to their maintenance on immunosuppressive regimens. Flares of psoriasis post-organ transplant are more rare and often require carefully thought-out management plans. Here we report the treatment of a patient who was diagnosed with new-onset psoriasis eight months after a kidney transplant. In discussion with his nephrologist, the decision was made to increase the doses of tacrolimus and mycophenolate mofetil.
LebwohlM.G., BachelezH., BarkerJ.. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.J Am Acad Dermatol.2014; 70(5): 871–881. e871–830.
BasavarajK.H., AshokN.M., RashmiR., PraveenT.K.. The role of drugs in the induction and/or exacerbation of psoriasis.Int J Dermatol.2010; 49(12): 1351–1361.
8.
FryL., BakerB.S.. Triggering psoriasis: the role of infections and medications.Clin Dermatol.2007; 25(6): 606–615.
9.
BalatoN., Di CostanzoL., PatrunoC., PatriA., AyalaF.. Effect of weather and environmental factors on the clinical course of psoriasis.Occup Environ Med.2013; 70(8): 600.
10.
ParkB.S., YounJ.I.. Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type.J Dermatol.1998; 25(2): 97–102.
11.
RadackK.P., FarhangianM.E., AndersonK.L., FeldmanS.R.. A review of the use of tanning beds as a dermatological treatment.Dermatol Ther.2015; 5(1): 37–51.
12.
RaczE., PrensE.P.. Phototherapy and photochemotherapy for psoriasis.Dermatol Clin.2015; 33(1): 79–89.
13.
JegasothyB.V., AckermanC.D., TodoS., FungJ.J., Abu-ElmagdK., StarzlT.E.. Tacrolimus (FK 506) — a new therapeutic agent for severe recalcitrant psoriasis.Arch Dermatol.1992; 128(6): 781–785.
14.
KanamoriH., TanakaM., KawaguchiH.. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature.Am J Hemtol.2002; 71(1): 41–44.
15.
MeleC., SalernoM.P., RomagnoliJ., De SimoneC., CastriotaM., CitterioF.. Complete clinical remission of psoriasis 6 months after renal transplantation.Transplant Proc.2013; 45(7): 2788–2789.
16.
CoulsonI.H., EvansC.D., HoldenC.A.. Generalized pustular psoriasis after renal transplantation — failure to suppress with cyclosporin A.Clin Exp Dermatol.1988; 13(6): 416–417.
17.
WeiK.C., LaiP.C.. Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.Dermatol Ther.2015; 28(1): 25–27.
ForoncewiczB., MuchaK., LerutJ., MajewskiS., KrawczykM., PaczekL.. Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis.Ann Transplant.2014; 19: 427–433.
20.
SinghG.K., ChatterjeeM.. Psoriatic erythroderma and hypothalamus-pituitary axis suppression due to misuse of systemic steroid: two challenging cases.Indian J Dermatol.2015; 60(2): 194–197.
21.
SaekiH., WatanabeA., TadaY.. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid.J Dermatol.2008; 35(9): 601–603.
22.
MrowietzU., DommS.. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?J Eur Acad Dermatol Venereol.2013; 27(8): 1022–1025.
23.
BakerH., RyanT.J.. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases.Br J Dermatol.1968; 80(12): 771–793.
24.
BrodellR.T., WilliamsL.. A corticosteroid-induced flare of psoriasis. How to control or, better yet, avoid.Postgrad Med.1999; 106(7): 31–32.
25.
NaldiL.. Epidemiology of psoriasis.Inflamm Allergy Drug Targets.2004; 3(2): 121–128.
BrennerM., MolinS., RuebsamK., WeisenseelP., RuzickaT., PrinzJ.C.. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment.Br J Dermatol.2009; 161(4): 964–966.
28.
PapanicolaouD.A., TsigosC., OldfieldE.H., ChrousosG.P.. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency?J Clin Endocrinol Metab.1996; 81(6): 2303–2306.
29.
ElderJ.T., BruceA.T., GudjonssonJ.E.. Molecular dissection of psoriasis: integrating genetics and biology.J Invest Dermatol.2010; 130(5): 1213–1226.
30.
LocksleyR.M., KilleenN., LenardoM.J.. The TNF and TNF receptor superfamilies: integrating mammalian biology.Cell.2001; 104(4): 487–501.
31.
BettelliE., OukkaM., KuchrooV.K.. T(H)-17 cells in the circle of immunity and autoimmunity.Nat Immunol.2007; 8(4): 345–350.
32.
KeijsersR.R., HendriksA.G., van ErpP.E.. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17.J Invest Dermatol.2014; 134(5): 1276–1284.
33.
Di CesareA., Di MeglioP., NestleF.O.. The IL-23/Th17 axis in the immunopathogenesis of psoriasis.J Invest Dermatol.2009; 129(6): 1339–1350.
34.
SchonM.P.. The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders.Exp Dermatol.2014; 23(11): 804–806.
35.
SehgalV.N., SrivastavaG., DograS.. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I.Skinmed.2008; 7(1): 27–30.
36.
ReynoldsN.J., Al-DarajiW.I.. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.Clin Exp Dermatol.2002; 27(7): 555–561.
37.
MarslandA.M., GriffithsC.E.. The macrolide immunosuppressants in dermatology: mechanisms of action.Eur J Dermatol.2002; 12(6): 618–622.
38.
LeungD.Y., SoterN.A.. Cellular and immunologic mechanisms in atopic dermatitis.J Am Acad Dermatol.2001; 44(1 Suppl): S1–s12.
39.
KinoT., HatanakaH., MiyataS.. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.J. Antibiot.1987. 40(9): 1256–1265.
40.
WangC., LinA.. Efficacy of topical calcineurin inhibitors in psoriasis.J Cutan Med Surg.2014; 18(1): 8–14.
41.
MittalA., DograS., NarangT., SharmaA.. Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis.J Cutan Med Surg.2015.
42.
CarrollC.L., FleischerA.B.Jr.. Tacrolimus ointment: the treatment of atopic dermatitis and other inflammatory cutaneous disease.Expert Opin Pharmacother.2004; 5(10): 2127–2137.
43.
LebwohlM., FreemanA.K., ChapmanM.S., FeldmanS.R., HartleJ.E., HenningA.. Tacrolimus ointment is effective for facial and intertriginous psoriasis.J Am Acad Dermatol.2004; 51(5): 723–730.
ScheinfeldN.. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review.Dermatol Online J.2004; 10(1): 3.
46.
ZonneveldI.M., RubinsA., JablonskaS.. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.Arch Dermatol.1998; 134(9): 1101–1102.
47.
RemitzA., ReitamoS., ErkkoP., GranlundH., LauermaA.I.. Tacrolimus ointment improves psoriasis in a microplaque assay.Br J Dermatol.1999; 141(1): 103–107.
48.
RansomJ.T.. Mechanism of action of mycophenolate mofetil.Ther Drug Monit.1995; 17(6): 681–684.
PedrazJ., DaudenE., Delgado-JimenezY., Garcia-RioI., Garcia-DiezA.. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.J Eur Acad Dermatol Venereol.2006; 20(6): 702–706.
51.
GeilenC.C., TebbeB., Garcia BartelsC., KrengelS., OrfanosC.E.. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil.Br J Dermatol.1998; 138(6): 1101–1102.
NousariH.C., SragovichA., Kimyai-AsadiA., OrlinskyD., AnhaltG.J.. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.J Am Acad Dermatol.1999; 40(2 Pt 1): 265–268.
54.
Grundmann-KollmannM., MooserG., SchraederP.. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil.J Am Acad Dermatol.2000; 42(5 Pt 1): 835–837.
55.
Fallah AraniS., Waalboer SpuijR., NijstenT., NeumannH.A., ThioB.. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study.J Dermatolog Treat.2014; 25(1): 46–49.
56.
SollingerH.W., SundbergA.K., LeversonG., VossB.J., PirschJ.D.. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.Transplantation.2010; 89(4): 446–451.
57.
ManginoM., SchenaF.P.. [Skin cancer in renal transplant recipients].Giornale italiano di nefrologia: organo ufficiale della Societa italiana di nefrologia.2010; 27 Suppl 50: S75–80.
58.
ZwaldF.O., BrownM.. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.J Am Acad Dermatol.2011; 65(2): 253–261; quiz 262.
59.
PonticelliC., CucchiariD., BenciniP.. Skin cancer in kidney transplant recipients.J Nephrol.2014; 27(4): 385–394.
60.
SpecchioF., SaracenoR., ChimentiS., NisticoS.. Management of non-melanoma skin cancer in solid organ transplant recipients.Int J Immunopathol Pharmacol.2014; 27(1): 21–24.
61.
SulowiczJ., Wojas-PelcA., IgnacakE., Betkowska-ProkopA., KuzniewskiM., SulowiczW.. [Risk factors of non melanoma skin cancers in kidney transplant patients].Przegl Lek.2014; 71(1): 19–25.
62.
Rodriguez-AcostaE.D., Calva-MercadoJ.J., Alberu-GomezJ., Vilatoba-ChapaM., Dominguez-CheritJ.. [Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].Gac Med Mex.2015; 151(1): 20–26.
63.
AlterM., SatzgerI., SchremH., KaltenbornA., KappA., GutzmerR.. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.J Dtsch Dermatol Ges.2014; 12(6): 480–488.
64.
EuvrardS., UlrichC., LefrancoisN.. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.Dermatol Surg.2004; 30(4 Pt 2): 628–633.
65.
NavarroM.D., Lopez-AndreuM., Rodriguez-BenotA., AgueraM.L., Del CastilloD., AljamaP.. Cancer incidence and survival in kidney transplant patients.Transplant Proc.2008; 40(9): 2936–2940.
66.
O'NeillJ.O., EdwardsL.B., TaylorD.O.. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.J Heart Lung Transplant.2006; 25(10): 1186–1191.
67.
UlrichC., JurgensenJ.S., DegenA.. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.Br J Dermatol.2009; 161 Suppl 3: 78–84.
